Internal Medicine

Medicine & Life Sciences

1. Acute Myeloid Leukemia 13%
2. Adenocarcinoma 18%
3. Adenoma 12%
4. Alaska Natives 13%
5. Anaplastic Thyroid Carcinoma 13%
6. Anthracyclines 13%
7. Aromatase Inhibitors 18%
8. B-Cell Chronic Lymphocytic Leukemia 25%
9. Barrett Esophagus 41%
10. Biomarkers 17%
11. Biopsy 25%
12. Bortezomib 19%
13. Breast 12%
14. Breast Neoplasms 100%
15. Cardiomyopathies 14%
16. Cholangiocarcinoma 26%
17. Cisplatin 12%
18. Clinical Trials 19%
19. Colon 13%
20. Colonoscopy 22%
21. Colorectal Neoplasms 17%
22. Confidence Intervals 27%
23. Constipation 12%
24. Cyclophosphamide 14%
25. Dexamethasone 17%
26. Dilated Cardiomyopathy 12%
27. Docetaxel 12%
28. Doxorubicin 12%
29. Drug Therapy 38%
30. Endoscopic Ultrasound-Guided Fine Needle Aspiration 14%
31. Endoscopy 26%
32. Extracellular Vesicles 12%
33. Fibrosis 12%
34. Fine Needle Biopsy 14%
35. Gastric Emptying 22%
36. Gastrointestinal Tract 12%
37. Gastroparesis 34%
38. Genes 20%
39. Guidelines 18%
40. Heart 15%
41. Heart Failure 15%
42. Heart Transplantation 12%
43. Hepatocellular Carcinoma 16%
44. human ERBB2 protein 22%
45. Incidence 18%
46. Interstitial Cells of Cajal 41%
47. Irritable Bowel Syndrome 29%
48. Kinesin 13%
49. Lasers 13%
50. Lenalidomide 23%
51. Letrozole 15%
52. Liver 15%
53. Liver Transplantation 35%
54. Lung 12%
55. Lymphoma 13%
56. Melanoma 22%
57. Meta-Analysis 20%
58. Mortality 22%
59. Multiple Myeloma 53%
60. Mutation 20%
61. Myocarditis 44%
62. Neoplasm Metastasis 14%
63. Neoplasms 91%
64. Non-Small Cell Lung Carcinoma 14%
65. Odds Ratio 12%
66. Paclitaxel 21%
67. Pancreatic Neoplasms 20%
68. pembrolizumab 13%
69. Pharmaceutical Preparations 13%
70. Photochemotherapy 12%
71. Placebos 18%
72. Polyps 22%
73. Population 17%
74. Progression-Free Survival 20%
75. Prostatic Neoplasms 18%
76. Proteins 14%
77. Pulmonary Arterial Hypertension 16%
78. Quality of Life 13%
79. Recurrence 25%
80. Registries 14%
81. Renal Cell Carcinoma 19%
82. Rituximab 15%
83. Safety 25%
84. Serum 17%
85. Smooth Muscle 13%
86. Stomach 22%
87. Survival 53%
88. Systematic Reviews 19%
89. T-Lymphocytes 17%
90. Tamoxifen 12%
91. taxane 14%
92. Therapeutics 72%
93. Thyroid Gland 14%
94. Thyroid Neoplasms 13%
95. Transplant Recipients 12%
96. Transplantation 12%
97. Transplants 25%
98. Trastuzumab 36%
99. Waldenstrom Macroglobulinemia 15%